Introduction
Ectopic ACTH syndrome was first described by Brown in 1928 (1). Many tumors, including small-cell lung carcinoma, thymoma, carcinoid, thyroid medullary carcinoma, pancreatic Langerhans cell carcinoma, and pheochromocytoma, have been reported to produce ACTH (2, 3). Among them, small-cell lung carcinomas and bronchial carcinoids are the most common and account for 55 % of ectopic ACTH producing tumors, while the others are rare (2). Here, wereport a case of ectopic ACTH syndrome caused by thymic atypical carcinoid. Although most atypical carcinoids are resistant to antineoplastic agents, this case showed a good response to combination chemotherapy with cisplatin (CDDP) and etoposide (VP16).
Case Report
A 21-year-old womanwas referred to our hospital in July 1999, complaining of facial edema, acne, and an irregular menstrual period. She was obese and her face was moonlike. There was a buffalo hump in her upper back, but no other significant findings were noted on physical examination. Endocrinological examinations revealed her plasma ACTH level at rest in the morning to be 180 pg/ml, plasma cortisol 25.7 jug/dl, and urinary 17-OHCS ll.5 mg/day.
Urinary 17-KS and basal levels of other pituitary hormones were normal (Table 1) . Plasma cortisol was not suppressed The diagnosis of ectopic ACTH syndrome was made and the mediastinal mass was suspected to be an ACTH producing tumor. Since there were no apparent metastatic lesions in the imaging studies, the tumor was resected in August 1999.
Intraoperatively, however, several lesions invading the pleura, epicardium, and right diaphragm were observed. All of these macroscopic invasive lesions were resected together.
The histopathological examination revealed the tumor cells to have grown in a trabecular pattern with mitoses and ro-
showing the characteristics of a neuroendocrine tumor (Fig. 2 ). Since the tumor accompanied normal thymus tissue, thymic atypical carcinoid was diagnosed.
Postoperatively, plasma ACTH and cortisol levels fell rapidly to within the normal range. She recovered uneventfully a nd was discharged two weeks later. Two months after surgery, however, follow-up CT scan revealed small recurrent nodules in the right interlobar pleura. The nodular lesions progressed rapidly, and other disseminated nodules became apparent in the pleura and on the right diaphragm (Fig. 3A) . ACTH and LDH levels increased and Cushing's symptoms, such as facial edema, acne, and hypokalemia re-appeared. Aggressive progression of the disseminated lesions caused massive pleural effusion and dyspnea (Fig. 3B) . Combination chemotherapies were considered, and the patient was administered CDDP 40 mg/ mVday and VP16 100 mg/m2/day intravenously on days 1 to 5 every 4 weeks. After three courses of this therapy, the pleural effusion disappeared completely, the tumor shrank (Fig. 3C) , and ACTH and LDH levels decreased. Grade 3 neutropenia (neutrophils >1,200/jlx1), thrombocytopenia (Platelets >38,000/jlx1), and grade 2 nausea were observed, but there were no other significant side effects. No renal function impairment was seen during three courses of therapy. Although the treatment was effective, one lesion in the interlobar pleura did not disappear completely (Fig. 3C ). we employed a less toxic carboplatin dose of 300 mg/m2 with VP16 120 mg/m2 every 2 or 3 weeks, and good tumor control w as achieved for nine months.
In December 2000, the tumor again showed gradual progression with increases in ACTH and LDH levels. Mitotane (o, p'-DDD) was administered in January 2001 and radiotherapy for the main thoracic tumor to achieve palliative mass reduction, but with limited effectiveness.
To control It was not particularly difficult to make the clinical diagnosis of ectopic ACTH syndrome in this case, because she had an apparent mediastinal tumor, elevated ACTH, and typical symptomatic hypercortisolemia which was not suppressed by the overnight 8 mg dexamethasone test. The diagnosis was confirmed by the rapid decrease in plasma ACTH after tumor resection. The clinical course of her atypical carcinoid was very aggressive. Although disseminated lesions in the pleura and diaphragm were all resected intraoperatively, relapse was seen only 2 months after the operation. Since the disseminated lesions were diffuse and multiple, systemic chemotherapy was the only option for controlling tumor progression. In general, carcinoid tumors are indolent. For isolated tumors, surgical resection is the treatment of choice. However, with dissemination, treatment is difficult.
Several chemotherapeutic regimens including streptozocin, cyclophosphamide, fluorouracil, and/or doxorubicin have been reported for metastatic carcinoids.
The response rates to those chemotherapies seldom exceeded 30%, and complete responses were uncommon(4-7). Two reported cases of thymic carcinoid with ectopic ACTH syndrome were refractory to chemotherapy (8, 9). However, for metastatic atypical carcinoids only, a high response rate (67%) has been reported with combination chemotherapy employi ng CDDP and VP16 (10).
We obtained informed consent from the patient and administered combination chemotherapy with CDDP and VP16. Weused higher doses of the chemotherapeutic agents than in the original regimen reported by Moertel et al (10) 
